Legionellosis (Legionnaires’ Disease & Pontiac Fever)

Infectious Agent

Gram-negative bacteria of the genus Legionella . Most cases of legionellosis are caused by Legionella pneumophila , but all species of Legionella can cause disease.

Transmission

Inhalation of a water aerosol containing the bacteria. The bacterium grows in warm freshwater environments. A single episode of possible person-to-person transmission of Legionnaires’ disease has been reported.

Epidemiology

Legionellae are ubiquitous worldwide. Disease occurs after exposure to aquatic settings that promote bacterial growth—the aquatic environment is somewhat stagnant, the water is warm (77°F–108°F [25°C–42°C]), and the water must be aerosolized so that the bacteria can be inhaled into the lungs. These 3 conditions are met almost exclusively in developed or industrialized settings. Disease does not occur in association with natural freshwater settings such as waterfalls, lakes, or streams.

Legionellosis has been reported worldwide. The largest outbreak (449 confirmed cases) ever reported was traced to a cooling tower on the roof of a city hospital in Murcia, Spain, in 2001. Travel-associated outbreaks are commonly recognized.

Despite the presence of Legionella bacteria in many aquatic environments, the risk of developing legionellosis for most people is low. Travelers who are exposed to aerosolized, warm water containing Legionella are at risk for infection. Travelers who are aged >50 years, are current or former smokers, have chronic lung conditions, or are immunocompromised are at higher risk. Many outbreaks have been associated with exposure to cruise ships, hotels, and resorts. Exposures can occur when a person is in or near a whirlpool spa, showering in a hotel, standing near a decorative fountain, or touring in cities with buildings that have cooling towers. Patients often do not recall specific water exposures, as they frequently occur during normal activities.

Clinical Presentation

Legionnaires’ disease typically presents with pneumonia, which usually requires hospitalization and can be fatal in 10%–15% of cases. Symptom onset occurs 2–10 days after exposure; rarely up to 19 days. In outbreak settings, <5% of people exposed to the source of the outbreak develop Legionnaires’ disease.

Pontiac fever is milder than Legionnaires’ disease and presents as an influenzalike illness, with fever, headache, and muscle aches, but no signs of pneumonia. Pontiac fever can affect healthy people, as well as those with underlying illnesses, and symptoms occur within 72 hours of exposure. Nearly all patients fully recover. Up to 95% of people exposed in outbreak settings can develop symptoms of Pontiac fever.

Diagnosis

Isolation of Legionella from respiratory secretions, lung tissue, pleural fluid, or a normally sterile site is an important method for diagnosis of Legionnaires’ disease. Clinical isolates are often necessary to interpret the findings of an investigation through comparison with isolates obtained from environmental sources. Because of differences in mechanism of disease, Legionella cannot be isolated in people who have Pontiac fever.

The most used diagnostic method is the Legionella urinary antigen assay. However, the assay can only detect L. pneumophila serogroup 1, the most common cause of legionellosis. Paired serology showing a 4-fold rise in antibody titer between acute- and convalescent-phase specimens also confirms the diagnosis. A single antibody titer of any level is not diagnostic of legionellosis. Other diagnostic tests include direct fluorescent antibody and PCR. Legionellosis is a nationally notifiable disease.

Treatment

For travelers with suspected Legionnaires’ disease, specific antibiotic treatment is necessary and should be administered promptly while diagnostic tests are being processed. Appropriate antibiotics include fluoroquinolones and macrolides. Treatment may be necessary for up to 3 weeks. In severe cases, patients may have prolonged stays in intensive care units. Consultation with an infectious disease specialist is advised. Pontiac fever is a self-limited illness that requires supportive care only; antibiotics have no benefit.

Prevention

There is no vaccine for legionellosis, and antibiotic prophylaxis is not effective. Travelers at increased risk for infection, such as the elderly or those with immunocompromising conditions such as cancer or diabetes, may choose to avoid high-risk areas, such as whirlpool spas. If exposure cannot be avoided, travelers should be advised to seek medical attention promptly if they develop symptoms of Legionnaires’ disease or Pontiac fever.

CDC website: www.cdc.gov/legionella

Bibliography

  1. Beer KD, Gargano JW, Roberts VA, Reses HE, Hill VR, Garrison LE, et al. Outbreaks associated with environmental and undetermined water exposures—United States, 2011–2012. MMWR Morb Mortal Wkly Rep. 2015 Aug 14;64(31):849–51.  [PMID:26270060]
  2. Burnsed LJ, Hicks LA, Smithee LM, Fields BS, Bradley KK, Pascoe N, et al. A large, travel-associated outbreak of legionellosis among hotel guests: utility of the urine antigen assay in confirming Pontiac fever. Clin Infect Dis. 2007 Jan 15;44(2):222–8.  [PMID:17173221]
  3. CDC. Legionellosis—United States, 2000–2009. MMWR Morb Mortal Wkly Rep. 2011 Aug 19;60(32):1083–6.  [PMID:21849965]
  4. CDC. Surveillance for travel-associated Legionnaires disease—United States, 2005–2006. MMWR Morb Mortal Wkly Rep. 2007 Dec 7;56(48):1261–3.  [PMID:18059257]
  5. Correia AM, Ferreira JS, Borges V, Nunes A, Gomes B, Capucho R, et al. Probable person-to-person transmission of Legionnaires’ disease. N Engl J Med. 2016 Feb 4;374(5):497–8.  [PMID:26840151]
  6. de Jong B, Payne Hallstrom L, Robesyn E, Ursut D, Zucs P, Eldsnet. Travel-associated Legionnaires’ disease in Europe, 2010. Euro Surveill. 2013;18(23):1–8.  [PMID:23449181]
  7. Garcia-Fulgueiras A, Navarro C, Fenoll D, Garcia J, Gonzalez-Diego P, Jimenez-Bunuales T, et al. Legionnaires’ disease outbreak in Murcia, Spain. Emerg Infect Dis. 2003 Aug;9(8):915–21.  [PMID:12967487]
  8. Guyard C, Low DE.Legionella infections and travel associated legionellosis. Travel Med Infect Dis. 2011 Jul;9(4):176–86.  [PMID:21995862]
  9. Mouchtouri VA, Rudge JW. Legionnaires’ disease in hotels and passenger ships: a systematic review of evidence, sources, and contributing factors. J Travel Med. 2015 Sep-Oct;22(5):325–37.  [PMID:26220258]
  10. Silk BJ, Moore MR, Bergtholdt M, Gorwitz RJ, Kozak NA, Tha MM, et al. Eight years of Legionnaires’ disease transmission in travellers to a condominium complex in Las Vegas, Nevada. Epidemiol Infect. 2012 Nov;140(11):1993–2002.  [PMID:22214820]

Authors

Preeta K. Kutty, Laurel E. Garrison